Clinical Trial Update: Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a humanized CAR-T targeting BCMA (ARI0002h) in relapsed/refractory multiple myeloma, undergoing Phase 1/Phase 2 evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ARI0002h

Snippet

Sponsor: Sara V. Latorre | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN